TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
Bristol-Myers Squibb Norway AS
Closing information (x1000 EUR)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
132,072
|
17,870
|
14,961 |
| Financial expenses |
397
|
33
|
47 |
| Earnings before taxes |
5,622
|
880
|
758 |
| Total assets |
54,232
|
23,847
|
23,911 |
| Current assets |
54,190
|
23,816
|
23,897 |
| Current liabilities |
22,993
|
5,283
|
4,912 |
| Equity capital |
31,239
|
18,564
|
19,000 |
| - share capital |
84
|
89
|
76 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
57.6%
|
77.8%
|
79.5% |
| Turnover per employee | |||
| Profit as a percentage of turnover |
4.3%
|
4.9%
|
5.1% |
| Return on assets (ROA) |
11.1%
|
3.8%
|
3.4% |
| Current ratio |
235.7%
|
450.8%
|
486.5% |
| Return on equity (ROE) |
18.0%
|
4.7%
|
4.0% |
| Change turnover |
115,115
|
3,860
|
-33,209 |
| Change turnover % |
679%
|
28%
|
-69% |
| Chg. No. of employees | |||
| Chg. No. of employees % |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.